Conclusion Breaking through a weight loss plateau can be challenging, but GLP-1 medications offer a promising solution
The 12-week ramp-up exists to minimize side effects and build tolerance
For instance, semaglutide has shown an impressive average weight loss of about 15% over 68 weeks, higher than many other options
Sudden vision changes (Medications that alter blood sugar can have various effects on vision and should be evaluated promptly by an eye doctor.)
In this review, we will keep the nomenclature of NAFLD (instead of MAFLD) since in most of the cited studies, patient enrollment was based on previous diagnostic criteria
Among injectables, Roche's CT-388 (enicepatide) showed 22.5% weight loss in Phase 2 at 48 weeks with no plateau reached, and Amgen's MariTide reached 20% at 52 weeks in Phase 2